Global Drug Delivery Technologies Market Analysis & Trends - Industry Forecast to 2030

Global Drug Delivery Technologies Market Analysis & Trends - Industry Forecast to 2030

Drug Delivery Technologies: Market Size

From $48.09 billion in 2024, the global Drug Delivery Technologies market is projected to reach $98.05 billion by 2030. Based on our analysis the market is expected to grow at a CAGR of 12.6% from 2024 - 2030 timeframe. Some of the prominent trends that the market is witnessing include increasing focus towards drug delivery systems with better safety and dosing outcomes, advancing the delivery of biopharmaceuticals, and research and funding for the development of needle-free drug delivery devices.

Global Drug Delivery Technologies Market: Market Dynamics

Controlled administration of medication is aided by advancements in drug delivery technologies. These systems control the rate at which a drug is released. In the past few decades, the practice of drug delivery has changed tremendously, and even greater changes are expected in the near future. Recent scientific advances by biomedical engineers have focused to understand the functional barriers to effective drug delivery, which includes delivery in the circulatory system and drug movement through cells and tissues. The development of new technological nasal drug delivery devices and the rising prevalence of chronic diseases are fueling the growth of the drug delivery technologies market across the globe. The higher focus on novel technologies is one of the key factors contributing to the growth of the market.

For instance, in 2019, AstraZeneca proclaimed that the US Food and Drug Administration (FDA) agreed the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the Fasenra Pen). Fasenra is the only respiratory biologic that offers the option of management at residence or in a doctor’s workplace with eight-week preservation dosing.

On the other hand, the frequent changes in the regulatory approval process of combination products are likely to obstruct the profit boundaries. In addition, the increasing patient population with respiratory problem will further boost the drug delivery technologies market.

Impact of COVID-19 on Drug Delivery Technologies

The COVID-19 pandemic has a negative impact on the drug delivery technologies market globally. The COVID-19 outbreak in 2024 led to international border controls, nationwide lockdowns, pharmaceutical manufacturing boundaries & limitations. This pandemic has hindered the fabrication and distribution of drug delivery technologies. COVID-19 would certainly influence chronic and infectious diseases patients and their care for the near future. Creating support networks for physicians and patients will assist to break down walls and give patients with suitable access to potentially life-saving services. Companies are anxious about the COVID-19 epidemic's impact on supply and demand. All these factors are having a negative impact on the drug delivery technologies sector, pushing the pharmaceutical industry and regulators to re-examine pharmaceutical supply chains.

By Route of Administration

Oral Drug Delivery Segment Dominate the Market

The Oral Drug Delivery segment is anticipated to have the largest share during the forecast period, due to rising R&D investment, growth in the biologics market, and increasing infiltration of health insurance. The oral drug delivery technique is the most general and preferred route of drug administration by both the physician and the patient, by far. The demand for this dosage form mostly lies in the expediency of intake and the availability of a broad window of the therapeutic index, which, in turn, lowers the possibility of toxicity and side effects. Over the last decade, oral release drug delivery systems received expansive attention due to their flexibility, reduced dosing frequency, and better patient compliance. For instance, in 2024, Progenity Inc. announced the positive preliminary preclinical data regarding the performance of its oral drug delivery system (DDS), the DDS capsule, which uses a proprietary autonomous localization technology designed to identify the ileal/ileocecal region of the GI tract.

By Geography

North America Region is Leading in the Global Market Place

North America emerged as the leading region and is also anticipated to dominate the market share in the coming years, due to the better adoption of improved drug delivery solutions as well as follow-up of advanced treatment approaches in healthcare. Moreover, the rapid growth of chronic diseases such as diabetes in the U.S. is driven by the increasing awareness and the ongoing R&D in advanced devices, coupled with new product launches are the major factors responsible for North America’s dominance.

List of the Key Players Profiled in the Market Include:

• 3M
• F.Hoffmann-La Roche Ltd.
• Sanofi
• Novartis AG
• Glaxosmithkline PLC
• Becton, Dickinson and Company
• Roche Holding AG
• Pfizer, Inc.
• Merck & Co., Inc.
• Vectura Group PLC
• Bayer AG
• Baxter International, Inc.
• Johnson & Johnson Services, Inc.
• The Dow Chemical Company
• Generex Biotechnology Corp.
• Takeda Pharmaceutical Company Limited

List of the Regions/Countries Profiled in the Market Include:

North America
• US
• Canada
• Mexico
Europe
• Germany
• U.K
• Italy
• France
• Spain
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• New Zealand
• Rest of Asia Pacific
Middle East
• Saudi Arabia
• UAE
• Rest of Middle East
Latin America
• Argentina
• Brazil
• Rest of Latin America
Rest of the World (RoW)
• South Africa
• Others